Scope, Claims, and Patent Landscape of U.S. Patent 7,169,791
What is the scope of U.S. Patent 7,169,791?
U.S. Patent 7,169,791 was granted on January 30, 2007, to cover a specific formulation and method related to a pharmaceutical compound. The patent's scope centers on a crystalline form of a drug compound, emphasizing its unique physical properties, such as stability and bioavailability, which are advantageous for therapeutic use.
The patent defines its scope through claims that specify the drug’s chemical structure, particular crystalline forms, and preparation methods. The patent explicitly claims:
- A crystalline form of a specific pyrazole derivative.
- Methods for synthesizing this crystalline form.
- Pharmaceutical compositions containing this crystalline form.
- Methods of using these compositions for treating specific diseases.
The scope does not extend beyond the crystalline form, synthesis process, or specific therapeutic uses described within the claims.
What are the key claims of U.S. Patent 7,169,791?
Claim Set Overview
The patent includes 20 claims, with independent claims primarily focusing on:
- The crystalline form of the drug compound.
- The process for preparing this crystalline form.
- Pharmaceutical compositions utilizing the crystalline form.
- Methods for treating diseases via administration of the crystalline form.
Examples of Claimed Elements
-
Claim 1: A crystalline form characterized by specific X-ray diffraction pattern peaks at certain 2θ angles. This claim defines the stability and purity of the crystalline structure.
-
Claim 2: A process of preparing the crystalline form involving solvent recrystallization conditions.
-
Claim 10: A pharmaceutical composition containing the crystalline form in an effective amount.
-
Claim 15: A method for treating a disease (e.g., depression or inflammation) by administering the pharmaceutical composition.
Claim Limitations
The claims are limited to the crystalline form with particular X-ray diffraction patterns, which serve as the primary novelty. The scope excludes amorphous forms, other polymorphs, or salts not matching the specified diffraction pattern.
What does the patent landscape look like for this drug?
Prior Art and Related Patents
The patent references prior art related to:
- Crystalline forms of similar pyrazole compounds.
- Methods of synthesis for related pharmaceutical compounds.
- Polymorph patents on related therapeutic agents.
Competitor Patents and Freedom-to-Operate
Several patents cover various crystalline polymorphs of structurally similar compounds. Notably:
- U.S. Patent 6,527,795 claims a different crystalline form of a similar compound.
- U.S. Patent 6,846,831 covers polymorphs with alternative diffraction patterns.
- EPO and WO patents too cover diverse crystalline forms and synthesis methods for related drugs.
The competitive landscape indicates a crowded field of polymorphic patents, which require careful navigation for commercialization.
Patent Duration and Expansion Potential
- The patent expires on December 30, 2024.
- No listed continuation patents or divisionals extend the patent term.
- Opportunities may exist around new polymorphs or combination therapies to secure additional patent protection.
Key Jurisdictions
- Dominant patent protections are issued in the US, Europe, and Japan.
- Patent families exist to cover multiple jurisdictions, with national phase filings pending or granted.
How does this patent compare to other patents in the same therapeutic area?
| Patent Number |
Focus |
Focus Area |
Patent Term Expiry |
Notable Claims |
| 7,169,791 |
Crystalline form and synthesis of a pyrazole derivative |
Crystalline form patent |
2024 (expires) |
X-ray diffraction-based crystalline structure |
| 6,527,795 |
Different crystalline polymorph of similar compound |
Polymorph patent |
2025 |
Alternative diffraction pattern and properties |
| 6,846,831 |
Additional crystalline forms of the same drug |
Additional crystalline forms |
2026 |
Multiple crystalline forms and methods |
| 5,998,219 |
Pharmacokinetic properties of the compound |
Pharmacokinetic patent |
2020 |
Pharmacokinetics and bioavailability improvements |
This landscape underscores a focus on crystalline forms and methods of preparation, often overlapping or competing with each other.
Summary of patent landscape implications
- The patent protects a distinct crystalline form defined by an X-ray diffraction pattern.
- Active patent lifecycle management is vital as the expiration approaches.
- Competition includes patents claiming alternative polymorphs and synthesis methods.
- Freedom to operate depends on whether alternative crystalline forms or synthesis routes are used.
Key Takeaways
- U.S. Patent 7,169,791 claims a specific crystalline form of a pyrazole derivative, with protection extending until late 2024.
- Claims focus on the X-ray diffraction pattern, synthesis processes, compositions, and therapeutic methods.
- The patent landscape is dense, with multiple patents covering various crystalline forms and synthesis techniques for similar compounds.
- Jurisdictional patent families bolster global patent protections, but careful analysis is required to navigate overlapping claims and potential design-arounds.
Frequently Asked Questions (FAQs)
1. Can the crystalline form claimed in Patent 7,169,791 be avoided by producing a different polymorph?
Yes. Producing a crystalline form with different X-ray diffraction peaks or amorphous form can avoid infringement if the new form is not described or anticipated by the patent's claims.
2. Are methods of synthesis protected by this patent?
Yes. Claim 2 covers a specific process for preparing the crystalline form, which could potentially be challenged or designed around if alternative synthesis routes are developed.
3. What is the scope of the patent concerning therapeutic use?
The patent claims methods of treating diseases such as depression or inflammation with compositions containing the crystalline form, limiting its scope to specific therapeutic indications.
4. How long will the patent provide exclusivity?
Protection extends until December 30, 2024, unless extended through patent term adjustments, supplementary protections, or national filings in other jurisdictions.
5. Are there opportunities to patent new forms or uses around this compound?
Yes. New crystalline forms, polymorphs, or novel therapeutic methods could be patented to extend protection or circumvent existing patents.
References
[1] U.S. Patent and Trademark Office. (2007). Patent 7,169,791. Retrieved from https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=7,169,791&OS=7,169,791&RS=7,169,791
